Table 5. Top signaling pathways implicated in progression of melanoma.
| Pathway | Nevus vs Skin | Pr. Mel vs Skin | Met. Mel vs Skin | Met. Mel vs Pr. Mel | Pr. Mel vs Nevus |
|---|---|---|---|---|---|
| Fas Signaling Pathway (Negative) | DOWN | UP | UP | UP | UP |
| cAMP Pathway (Glycolysis) | UP | DOWN | DOWN | UP | DOWN |
| CD40 Pathway (Cell Survival) | UP | UP | UP | UP | UP |
| AKT Pathway (Protein Synthesis) | UP | DOWN | DOWN | DOWN | DOWN |
| ATM Pathway (Apoptosis, Senescense) | DOWN | UP | UP | UP | UP |
| BRCA1 Main Pathway | UP | UP | UP | UP | UP |
| cAMP Pathway (Endothelial Cell Regulation) | UP | DOWN | DOWN | DOWN | DOWN |
| cAMP Pathway (Myocardial Contraction) | DOWN | DOWN | DOWN | DOWN | DOWN |
| cAMP Pathway (Protein Retention) | DOWN | UP | UP | UP | UP |
| Caspase Cascade (Apoptosis) | UP | DOWN | DOWN | DOWN | DOWN |
| CD40 Pathway (IKBs Degradation) | UP | UP | UP | UP | UP |
| DDR pathway Apoptosis | DOWN | UP | UP | UP | UP |
| Glucocorticoid Receptor Pathway (Cell cycle arrest) | UP | DOWN | DOWN | DOWN | DOWN |
| HGF Pathway (PKC pathway) | UP | UP | UP | UP | DOWN |
| HIF1-Alpha Main Pathway | UP | UP | UP | UP | UP |
| JNK Pathway (Insulin signaling) | UP | DOWN | DOWN | DOWN | DOWN |
| mTOR Pathway (VEGF pathway) | DOWN | DOWN | UP | UP | DOWN |
| PAK Pathway (Myosin Activation) | DOWN | DOWN | DOWN | DOWN | DOWN |
| Ubiquitin Proteasome Pathway (Degraded Protein) | DOWN | UP | UP | UP | UP |
UP or DOWN indicates positive and negative difference between the states of interest (nevus, primary and metastatic melanoma) and skin in median PAS value, respectively.